TABLE 2.
| Reference Products | Biosimilars (Year Approved) | Action |
|---|---|---|
| Insulin glargine | Basaglar*/Abasaglar† (2015/2014) Lusduna† (2017) Semglee (2020) |
Long-acting |
| Insulin lispro | Admelog* (2017) | Short-acting |
| Insulin aspart | Insulin aspart Sanofi (2020) Sar-Asp† (2020) Kixelle† (2021) |
Products approved in the United States before 23 March 2020 were termed “follow-on biologics.”
Approved in the European Union.